Profile: MDRNA is a biotechnology company focused on the development and commercialization of therapeutic products based on RNA interference (RNAi). We build a broad, flexible and cutting-edge drug discovery platform based on the premise that no single RNAi technology or delivery approach can overcome the target specific and indication specific challenges of down regulating protein expression via an siRNA therapeutic. We are involved in the discovery and development of novel siRNA therapeutics in the area of oncology, particularly in hepatocellular carcinoma (liver cancer) and bladder cancer and in critical unmet medical needs.

The company was founded in 1983, has revenues of USD 1-5 Million, has ~20 employees. NASDAQ:NSTK (SEC Filings)